Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment A | Experimental | Receive 50 mg BMS-986177 once daily or placebo |
|
| Treatment B | Experimental | Receive 200 mg BMS-986177 once daily or placebo |
|
| Treatment C | Experimental | Receive 500 mg BMS-986177 once daily or placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-986177 | Drug | Oral Suspension |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of Death | Measured by investigator assessment | 30 days after last dose |
| Incidence of Serious Adverse Events (SAEs) | Measured by investigator assessment | 30 days after last dose |
| Incidence of Adverse Events (AEs) Leading to Discontinuation of Study Therapy | Measured by investigator assessment | 17 days |
| Incidence of Adverse Events (AEs) Resulting in Clinically Significant Bleeding | Measured by investigator assessment | 17 days |
| Changes in Vital Signs (heart rate, systolic blood pressure, diastolic blood pressure, respiration rate, and temperature) | Measured by investigator assessment | 17 days |
| Change from baseline in electrocardiogram findings (ECGs) | Measured by investigator assessment | 17 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion and exclusion criteria apply
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| West Coast Clinical Trials | Anaheim | California | 90630 | United States |
Not provided
| Label | URL |
|---|---|
| FDA Safety Alerts and Recalls | View source |
| BMS Clinical Trial Information | View source |
| BMS clinical trial educational resource |
Not provided
Not provided
| ID | Term |
|---|---|
| D013927 | Thrombosis |
| ID | Term |
|---|---|
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000720754 | milvexian |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Matched Placebo |
| Other |
Oral Suspension |
|